Stem Cells

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

Retrieved on: 
금요일, 3월 8, 2024

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
  • “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
  • The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
  • Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
목요일, 3월 7, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
목요일, 3월 7, 2024

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

Novel Bio announces collaborative partnership with Culture Biosciences to scale-up NBx Platform™ for plasmid DNA production

Retrieved on: 
화요일, 3월 5, 2024

Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA for use in genetic medicines, announced today that they have formed a partnership with Culture Biosciences to accelerate the development of scalable fermentation processes for their proprietary NBx Platform™ for plasmid DNA production.

Key Points: 
  • Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA for use in genetic medicines, announced today that they have formed a partnership with Culture Biosciences to accelerate the development of scalable fermentation processes for their proprietary NBx Platform™ for plasmid DNA production.
  • View the full release here: https://www.businesswire.com/news/home/20240305254120/en/
    Since the 1970s, plasmid DNA has been produced using the simple bacterium E. coli.
  • For the past 2 years Novel Bio has been developing a new microbe to solve key manufacturing challenges.
  • “Instead, we decided to partner with Culture Biosciences to access their amazing team and their custom-built, cloud-connected bioreactors.

Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology

Retrieved on: 
월요일, 3월 4, 2024

This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kill cancer cells.

Key Points: 
  • This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kill cancer cells.
  • Biomunex, which was already co-inventor and a 50% co-owner of this unique innovative approach, now holds full worldwide rights.
  • In addition, MAIT cells present the MDR-12 protein on their surface, providing them with a natural resistance to some major chemotherapies.
  • “The research performed at Institut Curie has led to a major discovery which now opens up promising new therapeutic options.

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Retrieved on: 
월요일, 3월 4, 2024

Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.
  • The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents:
    Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2.
  • Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5.
  • Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6.

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Retrieved on: 
월요일, 3월 4, 2024

The closing of the offering is expected to occur on or about March 6, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 6, 2024, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • Total gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $2.0 million.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering.

ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
금요일, 3월 1, 2024

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced that Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME, and other members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, in Boston, Massachusetts.

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced that Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME, and other members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, in Boston, Massachusetts.

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

Retrieved on: 
목요일, 2월 29, 2024

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.

Key Points: 
  • Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.
  • Kenai Therapeutics previously raised seed funding under the name Ryne Bio.
  • Proceeds from the financing will enable the Company to submit an IND for RNDP-001 and complete Phase 1 clinical trials, which will initiate within the year.
  • “We are proud to be able to support Kenai in its mission to advance RNDP-001 to help families and patients suffering with this devastating disease.”

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
목요일, 2월 29, 2024

The DSMB recommended that the trial continue without modifications.

Key Points: 
  • The DSMB recommended that the trial continue without modifications.
  • The DSMB, composed of 4 independent experts, including an ALS patient association representative, concluded that safety was good.
  • More precisely, it should be noted that no serious or severe adverse events were observed, and no infectious events could be related to MaaT033.
  • The preliminary results reinforce confidence in the safety of MaaT033, a drug candidate produced by combining the microbiota from multiple donors using a "pooling" process.